The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Atara Biotherapeutics Inc shares valued at $38,437 were sold by Nguyen AnhCo on Nov 17 ’25. At $13.19 per share, Nguyen AnhCo sold 2,915 shares. The insider’s holdings dropped to 64,974 shares worth approximately $1.14 million following the completion of this transaction.
Also, Grant-Huerta Yanina sold 1,804 shares, netting a total of over 23,788 in proceeds. Following the sale of shares at $13.19 each, the insider now holds 33,454 shares.
Before that, Nguyen AnhCo had added 3,346 shares to its account. In a trade valued at $46,041, the Director bought Atara Biotherapeutics Inc shares for $13.76 each.
As published in a research note from Mizuho on November 09, 2023, Atara Biotherapeutics Inc [ATRA] has been rated down from a Buy to a Neutral and the price target has been revised to $1 from $31. Analysts at H.C. Wainwright downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in early November. As of November 09, 2023, Evercore ISI has decreased its “an Outperform” rating to a “an In-line” for ATRA. Earlier on July 20, 2022, Citigroup downgraded its rating. Their new recommendation was “a Sell” for ATRA stock which previously was a “a Neutral”.
Analyzing ATRA Stock Performance
On last trading session, Atara Biotherapeutics Inc [NASDAQ: ATRA] rose 0.51% to $17.59. The stock’s lowest price that day was $16.91, but it reached a high of $18.04 in the same session. During the last five days, there has been a surge of approximately 2.39%. Over the course of the year, Atara Biotherapeutics Inc shares have jumped approximately 54.30%. Shares of the company reached a 52-week high of $18.95 on 12/22/25 and a 52-week low of $5.01 on 04/07/25.
Support And Resistance Levels for Atara Biotherapeutics Inc (ATRA)
According to the 24-hour chart, there is a support level at 16.99, which, if violated, would cause prices to drop to 16.38. In the upper region, resistance lies at 18.12. The next price resistance is at 18.64. RSI (Relative Strength Index) is 63.12 on the 14-day chart, showing neutral technical sentiment.
Is Atara Biotherapeutics Inc subject to short interest?
Stocks of Atara Biotherapeutics Inc saw a sharp steep in short interest on 2025-11-28 dropping by 3836.0 shares to 0.16 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 0.17 million shares. A decline of -2.33% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 2.62 of the overall float, the days-to-cover ratio (short ratio) decline to 2.62.
Which companies own the most shares of Atara Biotherapeutics Inc (ATRA)?
In terms of Atara Biotherapeutics Inc share price expectations, FactSet research, analysts set an average price target of 25 in the next 12 months, up nearly 42.86% from the previous closing price of $17.5. Analysts anticipate Atara Biotherapeutics Inc stock to reach 25 by 2025, with the lowest price target being 25. In spite of this, 1 analysts ranked Atara Biotherapeutics Inc stock as Sell at the end of 2025. On July 13, 2022, Stifel assigned a price target of “a Hold” to the stock and downgraded coverage with a $5.
